NEOBIOTIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Neobiotic, and what generic alternatives are available?
Neobiotic is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in NEOBIOTIC is neomycin sulfate. There are nineteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the neomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neobiotic
A generic version of NEOBIOTIC was approved as neomycin sulfate by TEVA on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEOBIOTIC?
- What are the global sales for NEOBIOTIC?
- What is Average Wholesale Price for NEOBIOTIC?
Summary for NEOBIOTIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Patent Applications: | 29 |
| DailyMed Link: | NEOBIOTIC at DailyMed |
US Patents and Regulatory Information for NEOBIOTIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | NEOBIOTIC | neomycin sulfate | TABLET;ORAL | 060475-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
